Thor Petersen

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis et al. · Brain · 2016 · 401 citations · Full text

Neurological Disorder, Disability, Clinical Neurology +22

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Anna He, B. Merkel, J William L Brown et al. · The Lancet Neurology · 2020 · 401 citations · Full text

Disease Progression, Neurological Disorder, Clinical Epidemiology +7

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Per Soelberg Sørensen, Katja Maria Clemmesen, Klaus Bendtzen et al. · The Lancet · 2003 · 371 citations

Clinical Immunology, Relapsing-remitting Multiple Sclerosis, Autoimmune Disease +12

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Resistance training improves muscle strength and functional capacity in multiple sclerosis

Ulrik Dalgas, Egon Stenager, Johannes Jakobsen et al. · Neurology · 2009 · 271 citations